Alkermes plc. (ALKS) — SEC Filings

Latest SEC filings for Alkermes plc. (ALKS), explained in plain English.

Sentiment Overview: 2 bullish, 35 neutral, 2 mixed

Recent Filings (39)

• ARS Filing — ARS · 2026-04-06T17:16:53-04:00 [neutral]
• Alkermes Enters Material Definitive Agreement — 8-K · 2025-11-19T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. announced on November 18, 2025, that it has entered into a material definitive agreement. This agreement also creates a direct financial obligatio
• Alkermes plc. Files 8-K on Nov 12, 2025 — 8-K · 2025-11-12T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on November 12, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events
• Alkermes Q3 Net Income Dips Amid Rising Product Sales, R&D Spend — 10-Q · 2025-10-28T00:00:00.000Z [mixed] Risk: medium
  Alkermes plc reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenues for the three months increased to $39
• Alkermes plc. Files 8-K: Material Agreement & Financial Update — 8-K · 2025-10-22T00:00:00.000Z [neutral] Risk: medium
  On October 22, 2025, Alkermes plc. filed an 8-K report detailing a material definitive agreement and results of operations. The filing also disclosed the creati
• Alkermes plc. Files 8-K on Executive and Board Changes — 8-K · 2025-09-12T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on September 12, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of cer
• Alkermes plc. Files 8-K: Regulation FD & Financials — 8-K · 2025-09-08T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on September 8, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company'
• Alkermes Q2 Soars on LYBALVI, Net Income Jumps 25% — 10-Q · 2025-07-29T00:00:00.000Z [bullish] Risk: medium
  Alkermes plc. reported a robust financial performance for Q2 2025, with total revenues reaching $400.0 million, a significant increase from $370.0 million in Q2
• Alkermes plc. Files 8-K for Regulatory Disclosure — 8-K · 2025-07-21T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on July 21, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific fi
• Alkermes plc. Files 8-K: Director/Officer Changes & Shareholder Votes — 8-K · 2025-05-21T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on May 21, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain o
• Alkermes plc Files Definitive Proxy Statement — DEFA14A · 2025-05-12T00:00:00.000Z [neutral] Risk: low
  Alkermes plc filed a Definitive Proxy Statement (DEFA14A) on May 12, 2025. This filing is related to the company's proxy materials, likely for an upcoming share
• Alkermes Q1 2025 10-Q Filed — 10-Q · 2025-05-01T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. filed a 10-Q for the period ending March 31, 2025. The filing details financial performance, including revenue from key products like Vumerity and
• Alkermes Sells Lybalvi Rights to Sumitomo for $200M — 8-K · 2025-04-16T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. announced on April 14, 2025, that it has entered into a definitive agreement to sell its U.S. commercial rights to the schizophrenia drug Lybalvi
• Alkermes DEF 14A: Executive Compensation Details — DEF 14A · 2025-04-07T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. filed a DEF 14A on April 7, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information o
• Alkermes plc. Files 2024 10-K Annual Report — 10-K · 2025-02-12T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. filed its 2024 10-K on February 12, 2025, reporting on its fiscal year ending December 31, 2024. The company, a biopharmaceutical firm, operates i
• Alkermes plc. Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosur
• Alkermes plc. Terminates Material Definitive Agreement — 8-K · 2024-12-19T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. announced on December 19, 2024, the termination of a material definitive agreement. The company did not disclose the specific agreement or the cou
• Alkermes plc. Files 8-K — 8-K · 2024-12-02T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on December 2, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not con
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-08T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-04T00:00:00.000Z [neutral]
• Alkermes plc. Files Q3 2024 10-Q — 10-Q · 2024-10-24T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter. Spe
• Alkermes plc. Files 8-K for Routine Disclosures — 8-K · 2024-10-09T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on October 9, 2024, to report on Regulation FD disclosures and file financial statements and exhibits. The filing does not contain sp
• Alkermes plc. Files Q2 2024 10-Q — 10-Q · 2024-07-24T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key f
• Alkermes Files 8-K: Director Changes & Compensation Updates — 8-K · 2024-05-31T00:00:00.000Z [neutral] Risk: low
  Alkermes plc. filed an 8-K on May 31, 2024, reporting on the departure of a director, election of new directors, and changes in officer compensation. The filing
• Alkermes plc Files Definitive Proxy Statement — DEFA14A · 2024-05-14T00:00:00.000Z [neutral] Risk: low
  Alkermes plc filed a Definitive Proxy Statement (DEFA14A) on May 14, 2024, related to its annual general meeting. The filing details the company's governance, e
• Alkermes plc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-01T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. (ALKS) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Alkermes plc. filed a 10-Q report for the period ending March 31, 2024. The fi
• Alkermes plc sets May 31st Annual Meeting for director elections & pay votes — DEF 14A · 2024-04-15T00:00:00.000Z [neutral] Risk: low
  Alkermes plc has scheduled its 2024 Annual General Meeting of Shareholders for May 31, 2024, in Dublin, Ireland. Key agenda items include the election of direct
• Alkermes plc. Files 8-K Report — 8-K · 2024-04-09T00:00:00.000Z [neutral] Risk: low
  On April 9, 2024, Alkermes plc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. No
• Alkermes Appoints New Chief Medical Officer — 8-K · 2024-03-07T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. announced on March 5, 2024, the appointment of Dr. Craig R. Curtis as Chief Medical Officer. Dr. Curtis previously served as Executive Vice Presid
• Alkermes plc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-21T00:00:00.000Z [neutral] Risk: medium
  Alkermes plc. (ALKS) filed a Annual Report (10-K) with the SEC on February 21, 2024. Alkermes plc. filed its annual report on Form 10-K for the fiscal year endi
• Alkermes Files 8-K on Financial Condition and Operations — 8-K · 2024-02-15T00:00:00.000Z [neutral] Risk: low
  Alkermes Public Limited Company filed an 8-K Current Report on February 15, 2024. This filing, with CIK 0001520262, primarily concerns the company's "Results of
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Wellington Management Discloses Passive Stake in Alkermes plc. — SC 13G · 2024-02-08T00:00:00.000Z [bullish] Risk: low
  Wellington Management Group LLP, a major investment firm, filed an SC 13G on February 8, 2024, disclosing its ownership of Alkermes plc. (NASDAQ: ALKS) Common S
• Alkermes Reports Executive/Compensation Changes on Feb 1 — 8-K · 2024-02-05T00:00:00.000Z [neutral]
  Alkermes plc. filed an 8-K on February 5, 2024, reporting an event that occurred on February 1, 2024, related to the 'Departure of Directors or Certain Officers
• State Street Corp. Files SC 13G for Alkermes plc Stock — SC 13G · 2024-01-24T00:00:00.000Z [neutral]
  State Street Corporation, a major financial institution, reported an initial beneficial ownership filing (SC 13G) on January 24, 2024, for Alkermes plc. This fi
• BlackRock Cuts Alkermes Stake to 6.4% as of Dec 31, 2023 — SC 13G/A · 2024-01-08T00:00:00.000Z [mixed]
  BlackRock Inc. filed an amended Schedule 13G/A on January 8, 2024, indicating a change in its ownership stake in Alkermes plc. As of December 31, 2023, BlackRoc
• Alkermes Files Routine 8-K, Confirms Nasdaq Listing & Ireland Address — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Alkermes plc. filed an 8-K on January 8, 2024, to report a current event. This filing is a routine administrative update, primarily confirming the company's reg